Yang, Yunpeng

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) · The Lancet Oncology

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 462

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 390

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer

Hepatitis B Virus StudiesCancer Immunotherapy and Biomarkers

Cited by 185

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Adolescent endometriosis in China: a retrospective analysis of 63 cases

Yang, Y., Wang, Y., Yang, J., Wang, S., & Lang, J. (2012) · Journal of Pediatric and Adolescent Gynecology

Endometriosis Research and TreatmentGynecological conditions and treatments

Cited by 63

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019

Liu, J., Zhou, H., Zhang, Y., Fang, W., Yang, Y., Huang, Y., & Zhang, L. (2020) · Diabetes Care

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 55